OmniAb, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OABI | XNCR | AGEN | ZYME | AGMB | VRXA | |
|---|---|---|---|---|---|---|
| Market cap | 693.51M | 1.86B | 335.55M | 1.82B | 447.66M | 161.20M |
| P/E (TTM) | — | — | 2.9 | — | — | — |
| Forward P/E | -16.3 | -7.0 | -67.5 | 24.0 | -4.4 | — |
| Price/book | 2.7 | 3.7 | -1.6 | 22.5 | 3.6 | -0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +195.68% | +76.43% | +87.15% | +42.41% | −37.95% | −87.97% |
| Today | −0.42% | +1.66% | −3.13% | −1.78% | +0.11% | −9.52% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All OABI news ›VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
ZURICH, SWITZERLAND, July 27, 2026 --VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the 'Company'), an emerging leader in designing novel cancer the... VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program…
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
OmniAb executives emphasized the maturation of programs developed by partners using its technologies. The company said 34 active clinical programs and approved products had approximately $340 million in remaining potential contracted…
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
Formal presentation begins today, October 6, 2026, at 11 a.m. ET Featured Highlights at the Investor & Analyst Day: xPloration Platform – Plans and Outlook Beginning this month, the xPloration platform will be available for purchase by all…
OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow
(NASDAQ:OABI) 2026-10-06 Seeking Alpha The following slide deck was published by OmniAb, Inc. in conjunction with this event.
OmniAb (NASDAQ:OABI) Stock Jumps 3.1% – Should You Buy?
Posted by Danessa Lincoln on Oct 7th, 2026 OmniAb, Inc. (NASDAQ:OABI – Get Free Report) traded up 3.1% during mid-day trading on Wednesday. The company traded as high as $4.53 and last traded at $4.4850. Approximately 105,783 shares were…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
biospace.com2
-
defenseworld.net1
-
markets.businessinsider.com1
-
seekingalpha.com1
-
stocktitan.net1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.